PX 20350 - FXR agonist Cpd 22 |
| Catalog No.GB40336 |
Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1198085-23-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *